Espirit Pharma lands $91M in VC
|
VENTURE CAPITAL |
|||
|
COMPANY
|
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Esprit Pharma
|
$91M
|
New Enterprise Associates, Apax Partners, Domain Associates, Montagu Newhall Global Partners and Oak Investment Partners |
Esprit is focused on urology and women's health care specialty markets. |
|
ESBATech
|
$41M
|
SV Life Sciences, Clarus Ventures, HBM BioVentures and HBM BioCapital all participated with existing investors such as Novartis Venture Fund, BioMedinvest and VI Partners |
The company has been building a human antibody fragment platform. |
|
Acceleron
|
$30M
|
OrbiMed Advisors |
Acceleron's lead candidate is ACE-011, an experimental therapy for bone loss that is now in early-stage clinical trials. |
|
Cabrellis Pharmaceuticals
|
$27.5M
|
Domain Associates, Forward Ventures, Lilly Ventures, Novo A/S, ProQuest Investments, RBC Capital Partners, RiverVest Venture Partners, and S.R. One, Limited |
Cabrellis will use the money to advance its oncology candidates, in particular Calsed, its third-generation anthracycline currently in Phase II. |
|
Biodel
|
$21M
|
Great Point Partners, OrbiMed Advisors, and Vivo Ventures |
Biodel develops drug delivery technologies. |
|
Transport Pharmaceuticals
|
$12.6M
|
Quaker BioVentures |
Transport develops new therapies for dermatological conditions. |